Cystic Fibrosis Modulator Therapies

被引:25
|
作者
Jia, Shijing [1 ]
Taylor-Cousar, Jennifer L. [2 ,3 ]
机构
[1] Univ Michigan, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA
[2] Natl Jewish Hlth, Div Pulm Sci & Crit Care Med, Denver, CO USA
[3] Natl Jewish Hlth, Div Pediat Pulmonol, Denver, CO USA
来源
ANNUAL REVIEW OF MEDICINE | 2023年 / 74卷
关键词
cystic fibrosis; cystic fibrosis transmembrane conductance regulator; CFTR modulators; modulator therapies; PHE508DEL CFTR MUTATION; TEZACAFTOR-IVACAFTOR; LUMACAFTOR/IVACAFTOR COMBINATION; IN-VITRO; EFFICACY; SAFETY; IDENTIFICATION; POTENTIATOR; DISEASE; PEOPLE;
D O I
10.1146/annurev-med-042921-021447
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Cystic fibrosis (CF) is an inherited multisystemic disease that can cause progressive bronchiectasis, pancreatic endocrine and exocrine insufficiency, distal intestinal obstruction syndrome, liver dysfunction, and other disorders. Traditional therapies focused on the treatment or prevention of damage to each organ system with incremental modalities such as nebulized medications for the lungs, insulin for diabetes, and supplementation with pancreatic enzymes. However, the advent of highly effective modulator therapies that target specific cystic fibrosis transmembrane conductance regulator protein malformations resulting from individual genetic mutations has transformed the lives and prognosis for persons with CF.
引用
收藏
页码:413 / 426
页数:14
相关论文
共 50 条
  • [1] CFTR Modulator Therapies for Cystic Fibrosis
    Trimble, Aaron T.
    Donaldson, Scott H.
    [J]. PEDIATRIC ALLERGY IMMUNOLOGY AND PULMONOLOGY, 2015, 28 (04) : 230 - 236
  • [2] Cystic Fibrosis: Understanding Cystic Fibrosis Transmembrane Regulator Mutation Classification and Modulator Therapies
    Anwar, Saba
    Peng, Jin-Liang
    Zahid, Kashif Rafiq
    Zhou, Yu-Ming
    Ali, Qurban
    Qiu, Chong-Rong
    [J]. ADVANCES IN RESPIRATORY MEDICINE, 2024, 92 (04) : 263 - 277
  • [3] Trials and tribulations of highly effective modulator therapies in cystic fibrosis
    Lieu, Nathan
    Prentice, Bernadette J.
    Field, Penelope
    Fitzgerald, Dominic A.
    [J]. PAEDIATRIC RESPIRATORY REVIEWS, 2023, 48 : 10 - 19
  • [4] CFTR modulator therapies in pediatric cystic fibrosis: focus on ivacaftor
    Kramer, Elizabeth L.
    Clancy, John P.
    [J]. EXPERT OPINION ON ORPHAN DRUGS, 2016, 4 (10): : 1033 - 1042
  • [5] Lung Inflammatory Genes in Cystic Fibrosis and Their Relevance to Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapies
    Carbone, Annalucia
    Vitullo, Pamela
    Di Gioia, Sante
    Conese, Massimo
    [J]. GENES, 2023, 14 (10)
  • [6] CFTR Modulator Therapies: Potential Impact on Airway Infections in Cystic Fibrosis
    Saluzzo, Francesca
    Riberi, Luca
    Messore, Barbara
    Lore, Nicola Ivan
    Esposito, Irene
    Bignamini, Elisabetta
    De Rose, Virginia
    [J]. CELLS, 2022, 11 (07)
  • [7] Exercise intolerance in cystic fibrosis-the role of CFTR modulator therapies
    Caterini, Jessica E.
    Ratjen, Felix
    Barker, Alan R.
    Williams, Craig A.
    Rendall, Kate
    Schneiderman, Jane E.
    Wells, Greg D.
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2022, 21 (02) : 282 - 292
  • [8] Animal models of cystic fibrosis in the era of highly effective modulator therapies
    Grubb, Barbara R.
    Livraghi-Butrico, Alessandra
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2022, 64
  • [9] Effects of modulator therapies on endocrine complications in adults with cystic fibrosis: a narrative review
    Kumar, Shanal
    Soldatos, Georgia
    Teede, Helena J.
    Pallin, Michael
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 2023, 219 (10) : 496 - 502
  • [10] CFTR modulator therapies-Effect on life expectancy in people with cystic fibrosis
    Balfour-Lynn, I. M.
    King, J. A.
    [J]. PAEDIATRIC RESPIRATORY REVIEWS, 2022, 42 : 3 - 8